The trajectory of follow-up care for women undergoing a failed endometrial biopsy has been largely unexplored.
In a whole-exome analysis, the most common mutations occurred in TP53, and mutations in other known cancer-associated genes were identified in women with HPV-negative vulvar cancer.
Women with Stage I primary mucinous epithelial ovarian carcinoma who underwent uterus-preserving surgery did not have worse survival, a retrospective study found.
This study sought to address outstanding questions regarding tumor heterogeneity in the setting of HGSOC, including its relationship with treatment response.
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
Analysis of biomarkers to predict response to pembrolizumab are ongoing.
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
A longer treatment-free survival interval associated with surgery may contribute to overall survival.
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
Although ICI therapy has been shown to have limited efficacy in ovarian cancer (OC), some patients with OC do achieve long-term clinical benefit from this approach.
Clinicians may be underappreciating the extent of adverse events in women with cervical and endometrial cancer who undergo radiotherapy.
An analysis utilized the baseline characteristics of patients with pretreated ovarian cancer enrolled in a phase 3 trial to evaluate lifestyle interventions.
This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.
A key enrollment criterion in this randomized trial was a positive AGO score, a predictor of resectability in patients with recurrent ovarian cancer.
Delay in surgery for early-stage cervical cancer was not associated with worse short-term outcomes, supporting the suggestion to delay surgery in COVID-19 hotspots.
Olaparib should be new standard for maintenance in these patients.
Molecular subtypes, as indicated by the ProMisE classifier, of endometrial clear cell carcinoma are associated with different prognoses.
The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
Results showed a statistically significant improvement in PFS for Zejula compared with placebo, regardless of biomarker status.
One finding of this study was that the mutational landscapes of normal endometrial glandular tissue were influenced by patient age and parity.